Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sintilimab + GS neoadjuvant therapy for locally advanced biliary tract cancer (Phase II)
ChiCTR2400089592Phase 2Not yet recruiting
- Sponsor
- Third Affiliated Hospital of Naval Medical University
- Start
- Sep 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sintilimab in biliary cancer, sponsored by Third Affiliated Hospital of Naval Medical University. Primary endpoint: 1-year relapse-free survival rate. Planned start Sep 2024; status: not yet recruiting.
02
Drugs
sintilimab
03
Conditions
biliary cancer
Beyond the preview
Go deeper on ChiCTR2400089592.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400089592.